


PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING


FOR NON-IMMUNOCOMPROMISED POPULATIONS



Pfizer-BioNTech Ages 6 months–4 years

dose/injection volume
(dilute before use)


Maroon Cap



Pfizer-BioNTech Ages 5 years–11 years

dose/injection volume
(dilute before use)

Orange Cap



Pfizer-BioNTech Ages 12 years and older

dose/injection volume
(Do NOT dilute before use)

Gray Cap



See the [Pfizer-BioNTech COVID-19 Vaccine Guidance](#)

for children who are transitioning from a younger to older age group during their vaccination window.

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: [CDC](#).

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.